Accelovance Overview

  • Founded
  • 2005
Founded
  • Status
  • Acquired/​Merged
  • Latest Deal Type
  • M&A
  • Financing Rounds
  • 1
  • Investments
  • 5

Accelovance General Information

Description

Provider of clinical development contract research services intended to improve the quality and predictability in clinical research. The company's researches are focused on vaccine, oncology, dermatology, nutrition and women's health, enabling pharmaceutical companies, biotechs, CROs, and academic institutions to leverage operational knowledge and patient recruitment strategies in successful clinical trials.

Contact Information

Website
www.accelovance.com
Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Primary Industry
Other Healthcare Services
Acquirer
Linical Company
Primary Office
  • 2275 Research Boulevard
  • Suite 700
  • Rockville, MD 20850
  • United States
+1 (240) 000-0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Accelovance Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Accelovance‘s full profile, request access.

Request a free trial

Accelovance Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Provider of clinical development contract research services intended to improve the quality and predictability in clinic
Other Healthcare Services
Rockville, MD
00.00 0000-00-00
000000&0

00000-00

iqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commo
00000 0000000000 00000000
Houston, TX
00000
0000000 0000 00000

00000000

tion ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit
0000000000 00000000 (0000000000)
Morrisville, NC
000 As of 0000
00000
000000000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Accelovance Competitors (12)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Pharm-Olam International Private Equity-Backed Houston, TX 00000 0000000 0000 00000
000000000 00000000 Private Equity-Backed Morrisville, NC 000 00000 000000000000 00000
000 - (0000000 000 Corporation New York, NY
000 00000000 Corporation Burlingame, CA
00000 0000000 Corporation Dickinson, ND 00 000000000 -
You’re viewing 5 of 12 competitors. Get the full list »

Accelovance Executive Team (9)

Name Title Board Seat Contact Info
Stephen Trevisan Co-Founder, Chief Executive Officer & President
Vita Lanoce Chief Executive Officer, Linical Accelovance
Joseph Angle Jr. Chief Financial Officer & Co-Founder
Jamie Oliver Chief Science Officer
John Naples Finance Director
You’re viewing 5 of 9 executive team members. Get the full list »

Accelovance Board Members (1)

Name Representing Role Since
00000000 000000 00.0 Self Chairman, Clinical and Scientific Advisory Board 000 0000
To view Accelovance’s complete board members history, request access »

Accelovance Acquisitions (5)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
000000000000 00000 26-May-2016 000000000000000000 Drug Discovery 0000000 00000000
000000000 00000 02-Dec-2015 000000000000000000 Discovery Tools (Healthcare) 0000000 00000000
000000 00000000 05-Feb-2015 000000000000000000 Other Healthcare Services 0000000 00000000
0000000 0000000000 06-Mar-2013 000000000000000000 Practice Management (Healthcare) 0000000 00000000
nTouch Research 01-Feb-2005 Merger/Acquisition Drug Discovery
To view Accelovance’s complete acquisitions history, request access »

Accelovance Subsidiaries (1)

Company Name Industry Location Founded
000000000 00000 Discovery Tools (Healthcare) Amsterdam, Netherlands 0000
To view Accelovance’s complete subsidiaries history, request access »